Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

402 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dot pattern generation technique using molecular dynamics.
Idé T, Mizuta H, Numata H, Taira Y, Suzuki M, Noguchi M, Katsu Y. Idé T, et al. Among authors: taira y. J Opt Soc Am A Opt Image Sci Vis. 2003 Feb;20(2):248-55. doi: 10.1364/josaa.20.000248. J Opt Soc Am A Opt Image Sci Vis. 2003. PMID: 12570291
Participation of transcription elongation factor XSII-K1 in mesoderm-derived tissue development in Xenopus laevis.
Taira Y, Kubo T, Natori S. Taira Y, et al. J Biol Chem. 2000 Oct 13;275(41):32011-5. doi: 10.1074/jbc.M003920200. J Biol Chem. 2000. PMID: 10900206 Free article.
This S-II, named XSII-K1, is assumed to be the Xenopus homologue of mouse SII-K1 that we reported previously (Taira, Y., Kubo, T., and Natori, S. (1998) Genes Cells 3, 289-296). Expression of the XSII-K1 gene was found to be restricted to mesoderm-derived tissues su …
This S-II, named XSII-K1, is assumed to be the Xenopus homologue of mouse SII-K1 that we reported previously (Taira, Y., Kubo, …
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.
Vergote I, González-Martín A, Fujiwara K, Kalbacher E, Bagaméri A, Ghamande S, Lee JY, Banerjee S, Maluf FC, Lorusso D, Yonemori K, Van Nieuwenhuysen E, Manso L, Woelber L, Westermann A, Covens A, Hasegawa K, Kim BG, Raimondo M, Bjurberg M, Cruz FM, Angelergues A, Cibula D, Barraclough L, Oaknin A, Gennigens C, Nicacio L, Teng MSL, Whalley E, Soumaoro I, Slomovitz BM; innovaTV 301/ENGOT-cx12/GOG-3057 Collaborators. Vergote I, et al. N Engl J Med. 2024 Jul 4;391(1):44-55. doi: 10.1056/NEJMoa2313811. N Engl J Med. 2024. PMID: 38959480 Clinical Trial.
Mechanisms of action and resistance in histone methylation-targeted therapy.
Yamagishi M, Kuze Y, Kobayashi S, Nakashima M, Morishima S, Kawamata T, Makiyama J, Suzuki K, Seki M, Abe K, Imamura K, Watanabe E, Tsuchiya K, Yasumatsu I, Takayama G, Hizukuri Y, Ito K, Taira Y, Nannya Y, Tojo A, Watanabe T, Tsutsumi S, Suzuki Y, Uchimaru K. Yamagishi M, et al. Among authors: taira y. Nature. 2024 Mar;627(8002):221-228. doi: 10.1038/s41586-024-07103-x. Epub 2024 Feb 21. Nature. 2024. PMID: 38383791 Free PMC article.
402 results